Evidence map›Paper›PMID 35503286›Full record

ArticleRSC advances2020

Correction: Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation.

Vegard Torp Lien, Margrethe Konstanse Kristiansen, Solveig Pettersen, Mads Haugland Haugen, Stefan Krauss, Dag Erlend Olberg, Jo Waaler, Jo Klaveness

Abstract readPublished Erratum
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Vegard Torp LienDepartment of Pharmacy, University of Oslo Oslo Norway v.t.lien@farmasi.uio.no.
Margrethe Konstanse KristiansenDepartment of Pharmacy, University of Oslo Oslo Norway v.t.lien@farmasi.uio.no.
Solveig PettersenDepartment of Tumor Biology, Institute for Cancer Research, OUS Radiumhospitalet Oslo Norway.
Mads Haugland HaugenDepartment of Tumor Biology, Institute for Cancer Research, OUS Radiumhospitalet Oslo Norway.
Stefan KraussHybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo Oslo Norway.
Dag Erlend OlbergDepartment of Pharmacy, University of Oslo Oslo Norway v.t.lien@farmasi.uio.no.
Jo WaalerHybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo Oslo Norway.
Jo KlavenessDepartment of Pharmacy, University of Oslo Oslo Norway v.t.lien@farmasi.uio.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.1039/C9RA08954C.].

Identifiers

PMID35503286
PMCPMC9049247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.